Tanvex BioPharma Inc (TW:6541) — Stock Price
Tanvex BioPharma Inc (TW:6541) is currently trading at NT$38.80 TWD, up 1.97% today. Over the past 52 weeks, shares have ranged between NT$36.60 and NT$65.30. This page tracks Tanvex BioPharma Inc's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Tanvex BioPharma Inc market cap and net worth.
Tanvex BioPharma Inc (6541) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Tanvex BioPharma Inc's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Tanvex BioPharma Inc Income Statement — Revenue, Profit & Earnings by Year
Tanvex BioPharma Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$400.97 Million | NT$34.68 Million | NT$61.41 Million | NT$22.40 Million | NT$5.41 Million |
| Cost of Revenue | NT$841.68 Million | NT$26.39 Million | NT$1.71 Million | NT$41.75 Million | NT$1.86 Million |
| Gross Profit | NT$-440.71 Million | NT$8.29 Million | NT$59.70 Million | NT$-19.35 Million | NT$3.55 Million |
| Research & Development | NT$187.57 Million | NT$1.06 Billion | NT$1.71 Billion | NT$1.35 Billion | NT$1.38 Billion |
| SG&A | NT$430.19 Million | NT$261.84 Million | NT$404.29 Million | NT$208.75 Million | NT$176.78 Million |
| Total Operating Expenses | NT$947.48 Million | NT$1.37 Billion | NT$2.16 Billion | NT$1.59 Billion | NT$1.60 Billion |
| Operating Income | NT$-1.39 Billion | NT$-1.36 Billion | NT$-2.10 Billion | NT$-1.59 Billion | NT$-1.50 Billion |
| EBITDA | NT$-1.02 Billion | NT$-1.04 Billion | NT$-1.75 Billion | NT$-1.30 Billion | NT$-1.25 Billion |
| EBIT | NT$-1.39 Billion | NT$-1.33 Billion | NT$-2.08 Billion | NT$-1.59 Billion | NT$-1.50 Billion |
| Interest Expense | NT$47.23 Million | NT$53.34 Million | NT$57.38 Million | NT$54.72 Million | NT$46.22 Million |
| Income Before Tax | NT$-1.50 Billion | NT$-1.38 Billion | NT$-2.14 Billion | NT$-1.64 Billion | NT$-1.54 Billion |
| Income Tax Expense | NT$-3.05 Million | NT$347.00K | NT$428.00K | NT$23.00K | NT$22.00K |
| Net Income | NT$-1.50 Billion | NT$-1.38 Billion | NT$-2.14 Billion | NT$-1.64 Billion | NT$-1.54 Billion |
Tanvex BioPharma Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Tanvex BioPharma Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$7.96 Billion | NT$2.74 Billion | NT$2.76 Billion | NT$3.42 Billion | NT$4.71 Billion |
| Total Current Assets | NT$1.50 Billion | NT$675.62 Million | NT$604.21 Million | NT$1.04 Billion | NT$2.40 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | NT$123.23 Million | NT$939.00K | NT$10.36 Million | NT$2.76 Million | NT$2.52 Million |
| Inventory | NT$416.48 Million | NT$217.84 Million | NT$108.28 Million | NT$170.84 Million | NT$90.33 Million |
| Property, Plant & Equipment | — | — | — | NT$2.15 Billion | NT$2.11 Billion |
| Goodwill | NT$2.91 Billion | — | — | — | — |
| Total Liabilities | NT$2.27 Billion | NT$1.84 Billion | NT$1.94 Billion | NT$2.03 Billion | NT$1.92 Billion |
| Total Current Liabilities | NT$799.66 Million | NT$348.14 Million | NT$363.73 Million | NT$303.29 Million | NT$248.51 Million |
| Long-term Debt | — | — | — | — | NT$0.00 |
| Net Debt | NT$699.69 Million | NT$1.27 Billion | NT$1.35 Billion | NT$1.05 Billion | NT$-463.95 Million |
| Total Stockholder Equity | NT$5.69 Billion | NT$893.31 Million | NT$821.11 Million | NT$1.39 Billion | NT$2.79 Billion |
| Retained Earnings | NT$-15.64 Billion | NT$-14.14 Billion | NT$-12.75 Billion | NT$-12.97 Billion | NT$-11.33 Billion |
Tanvex BioPharma Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Tanvex BioPharma Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$-1.01 Billion | NT$-1.15 Billion | NT$-1.43 Billion | NT$-1.33 Billion | NT$-1.39 Billion |
| Capital Expenditures | NT$670.20 Million | NT$110.77 Million | NT$71.34 Million | NT$96.08 Million | NT$30.35 Million |
| Free Cash Flow | NT$-1.68 Billion | NT$-1.26 Billion | NT$-1.51 Billion | NT$-1.43 Billion | NT$-1.42 Billion |
| Investing Cash Flow | NT$301.80 Million | NT$-109.25 Million | NT$-83.57 Million | NT$-97.35 Million | NT$-24.68 Million |
| Financing Cash Flow | NT$1.14 Billion | NT$1.26 Billion | NT$1.08 Billion | NT$-123.29 Million | NT$1.60 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | NT$9.07 Million | NT$-2.16 Million | NT$326.61 Million | NT$67.55 Million | NT$52.95 Million |
| Depreciation | NT$366.73 Million | NT$289.04 Million | NT$324.83 Million | NT$281.56 Million | NT$243.58 Million |
| Change in Cash | NT$501.75 Million | NT$-3.79 Million | NT$-405.48 Million | NT$-1.44 Billion | NT$154.37 Million |
Tanvex BioPharma Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Tanvex BioPharma Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 05, 2026 | — | — | — |
| Mar 12, 2026 | — | — | — |
| Nov 06, 2025 | — | — | — |
| Aug 07, 2025 | — | — | — |
| May 07, 2025 | — | — | — |
| Mar 12, 2025 | — | — | — |
| Nov 08, 2024 | — | — | — |
| Nov 13, 2023 | -3.78 | — | — |